Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) Return on Equity (2017 - 2024)

KalVista Pharmaceuticals' Return on Equity history spans 9 years, with the latest figure at 0.88% for Q4 2024.

  • For Q4 2024, Return on Equity changed N/A year-over-year to 0.88%; the TTM value through Dec 2024 reached 0.88%, changed N/A, while the annual FY2020 figure was 0.07%, 27.0% up from the prior year.
  • Return on Equity for Q4 2024 was 0.88% at KalVista Pharmaceuticals, up from 1.05% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.44% in Q1 2020 and bottomed at 1.05% in Q4 2024.
  • The 4-year median for Return on Equity is 0.73% (2020), against an average of 0.73%.
  • The largest YoY upside for Return on Equity was -8bps in 2024 against a maximum downside of -40bps in 2024.
  • A 4-year view of Return on Equity shows it stood at 0.68% in 2020, then decreased by -13bps to 0.78% in 2021, then rose by 16bps to 0.65% in 2023, then plummeted by -36bps to 0.88% in 2024.
  • Per Business Quant, the three most recent readings for KALV's Return on Equity are 0.88% (Q4 2024), 1.05% (Q4 2024), and 0.77% (Q3 2024).